SIDE-BY-SIDE EVIDENCE
Compare evidence.
Keep the context.
Select 2–3 profiles from the English Library. Class and grade describe evidence and regulatory context, not comparative effectiveness or suitability for an individual.
Choose profilesSIDE-BY-SIDE EVIDENCE VIEW
Compare selected profiles
| Molecule |  Stanozolol | Oxandrolone | Testosterone |
|---|---|---|---|
| Research Topic | Clinical / Endocrine Pharmacology | Clinical / Endocrine Pharmacology | Clinical / Endocrine Pharmacology |
| Pharmacology | Synthetic anabolic-androgenic steroid | Oral anabolic-androgenic steroid with product-specific medical history | Endogenous androgen / prescription androgen medicine |
| PrimeCore Class | Class BInvestigational | Class BInvestigational | Class AApproved in a bounded context |
| Evidence Grade | Grade DLimited / observational evidence | Grade DLimited / observational evidence | Grade AStrong regulatory + clinical evidence |
| Evidence boundary | Stanozolol is classified here as Synthetic anabolic-androgenic steroid. Historical clinical use and class effects do not establish safe bodybuilding use or equivalence of oil and suspension catalogue entries. DEA lists stanozolol among commonly encountered anabolic steroids; prohibited by WADA at all times and supplier formulations are unverified. A catalogue name does not establish identity, formulation, quality or authorisation, and this page provides no dosage, mixing, injection or purchasing instructions. | Oxandrolone is classified here as Oral anabolic-androgenic steroid with product-specific medical history. Bounded medical evidence does not establish safety or effectiveness for physique or athletic use. A controlled anabolic steroid in the United States; exact current approved-product status must be checked and WADA prohibits it at all times. A catalogue name does not establish identity, formulation, quality or authorisation, and this page provides no dosage, mixing, injection or purchasing instructions. | Testosterone is an endogenous androgen and an active ingredient in authorised prescription medicines, but 'Test' does not identify an ester, formulation, strength, manufacturer or authorisation. Cypionate, enanthate, undecanoate, propionate, no-ester formulations and blends are not automatically interchangeable. TRAVERSE found MACE noninferiority for a specific gel in a defined population while other safety signals remained. This evidence does not authenticate catalogue products or support performance use. WADA 2026 prohibits testosterone and its esters at all times. |
| Unknowns | Insufficient data in the current dataset | Insufficient data in the current dataset | Insufficient data in the current dataset |
| Limitations |
|
|
|
| Sources | |||
| Read more | Read English overview | Read English overview | Read English overview |
This table does not compare doses, cross-trial outcomes or individual suitability. Missing information does not establish an absence of risk.
Choose another comparisonContinue reading
Missing fields mean information is unavailable in the current structured dataset, not that a molecule has no risks or uncertainties. English translations retain the original evidence boundaries. Where translation is not yet verified, the original Thai excerpts remain available under an explicit label. Sources retain their original language.
10 questions before drawing conclusions